Lawrence Lum

Director of Cellular Therapy, Scientific Director of Bone Marrow Transplant, Medicine- Hematology and Oncology · University of Virginia Medical Center

Credentials: · · ·

History

University of Virginia Medical Center
Present

Hematology and Medical Oncology
Internal Medicine
University of California-San Francisco
Chemistry, University of Redlands

Research

Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer
Nature Chemical Biology · 2009 · Last of 14 authors · Corresponding · 1,182 citations
The Hedgehog response network: sensors, switches, and routers
Review · Science · 2004 · First of 2 authors · 682 citations
The kinetics of immune reconstitution after human marrow transplantation
Review · Blood · 1987 · Sole author · 437 citations

Joseph Uberti
35 papers
VR
Voravit Ratanatharathorn
34 papers
Rainer Storb
26 papers
Abinhav Deol
24 papers
Zaid Al-Kadhimi
19 papers
Lois Ayash
18 papers
RW
Robert Witherspoon
14 papers
CK
Chatchada Karanes
11 papers
Keith Sullivan
9 papers
James Amatruda
8 papers
LS
Lyle Sensenbrenner
8 papers
Peter Quesenberry
8 papers

Grants

Targeting Neuroblastoma with Armed T Cells
National Cancer Institute · R01
Contact PI · $3.9M · University of Virginia
2014–2021
Enhancing Neoadjuvant Chemotherpay Responses with Targeted T Cells
National Cancer Institute · R01
Contact PI · $2M · Wayne State University
2010–2016
Breast Cancer Treatment with Antibody Targeted T Cells
National Cancer Institute · R01
Contact PI · $4.6M · Wayne State University
2002–2014

Clinical trials

Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent
Principal investigator · Withdrawn · Phase 1
Barbara Ann Karmanos Cancer Institute
2015–2017
Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Principal investigator · Withdrawn · Phase 1
Barbara Ann Karmanos Cancer Institute
2007–2008
Chemotherapy Followed by Peripheral Stem Cell Transplantation Plus Biological Therapy in Treating Women With Stage IV Breast Cancer
Study chair · Terminated · Phase 2
Barbara Ann Karmanos Cancer Institute
2007–2013
Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma
Study chair · Completed · Phase 1
Barbara Ann Karmanos Cancer Institute
2004–2013